Comparing the effectiveness and safety of oral zinc, oral doxycycline, and their combination therapy for treating patients with mild to moderate facial acne using benzoyl peroxide as standard treatment.

A comparative study on efficacy and safety of oral zinc vs oral doxycycline vs combined oral zinc and doxycycline in treatment of mild to moderate facial acne vulgaris with topical benzoyl peroxide as common standard therapy - a randomised controlled trial - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097541

Enrollment

Registered

2025-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: administration of Oral Zinc Acetate (50 mg elemental zinc): Oral Zinc Acetate (50 mg elemental zinc) once daily for 8 weeks + Topical Benzoyl Peroxide 2.5 % gel once nightly as common s

Eligibility

Inclusion criteria

Inclusion criteria: Age group 18-35 years Male or Female patients Clinically diagnosed with acne vulgaris of grades I , II , III. More than 10 lesion count Agreed to sign the consent to be included in the study

Exclusion criteria

Exclusion criteria: systemic antibiotics in last 4 weeks , systemic isotretinoin in last 6 months known allergy to study medications Additional facial dermatoses (atopic and seborrheic dermatitis) severe nodulocystic acne Female Patients who are pregnant and lactating.

Design outcomes

Primary

Measure	Time frame
Change in Global Acne Grading System (GAGS) score from baseline to week 4 and week 8 of treatmentTimepoint: Baseline, week 4, and week 8.	—

Secondary

Measure	Time frame
Change in total lesion counts from baseline to week 4 and week 8.Timepoint: Baseline, week 4, and week 8.;Assessment of side effect profile and adverse drug reactions during treatment. Timepoint: Continuously monitored throughout the 8-week study period.	—

Countries

India

Contacts

Public ContactDr Ashish Deshmukh

MGM Medical college and Hospital Aurangabad

ashish7557@gmail.com9422213292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026